Library / Repair / Larazotide
AT-1001 · tight-junction peptide
Larazotide
Trial
ClassZonulin-pathway octapeptide
Typical routes in papersOral in trials
Half-life contextLocal gut action intended
EvidenceCeliac / barrier trials (mixed late-stage)
What it is
Larazotide is an oral peptide meant to keep intestinal tight junctions tight when gluten or inflammation tries to pry them open.
Benefits in plain language
What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.
- The plain-language goal is less “leaky gut” signal in celiac disease, as an add-on to a gluten-free diet.
- It is one of the few barrier peptides that went into modern late-stage trials.
- Not a muscle-repair analog of BPC; different job.
If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.
Mechanism of action
Competes with zonulin-related opening of paracellular pores; intended to preserve occludin/ZO-1 function.
Possible side effects / caveats
Mostly GI and the disappointment risk of mixed trial readouts. Still investigational in the US sense.
Protocol ranges
| Source tier | Amount | Frequency / duration | Notes |
|---|---|---|---|
| Trial citations | 0.5–1 mg oral class in some arms | TID with meals often | Read current development news |
Numbers below and above are literature or community pointers, not a treatment plan. Approved products, when they exist, follow the official label — not a research vial.